# Achieve Life Sciences clinical trials: 31 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with Achieve Life Sciences as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Achieve Life Sciences: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/achieve-life-sciences

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 6, 2026 | NCT07392125 | Phase 3 Trial Evaluating the Efficacy and Safety of Cytisinicline for Vaping Cessation in Adults Using Nicotine-Containing E Cigarettes | Achieve Life Sciences | Phase 3 | Not yet recruiting | Vaping Cessation | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392125) |
| May 30, 2024 | NCT06435221 | Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers | Achieve Life Sciences | Phase 3 | Completed | Smoking Cessation, Vaping Cessation | 479 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06435221) |
| August 8, 2023 | NCT05981768 | Study to Evaluate Effect of Food on Bioavailability of Single 3 mg Tablet and Pharmacokinetics (PK) of Multiple 3 mg Doses in Healthy Adult... | Achieve Life Sciences | Phase 1 | Completed | Smoking Cessation | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05981768) |
| November 30, 2022 | NCT05631938 | Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose | Achieve Life Sciences | Phase 1 | Completed | Renal Impairment | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05631938) |
| October 4, 2022 | NCT05566288 | Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers | Achieve Life Sciences | Phase 1 | Completed | Smoking Cessation | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05566288) |
| June 24, 2022 | NCT05431387 | A Study of Cytisinicline for Vaping Cessation in Adult Smokers | Achieve Life Sciences | Phase 2 | Completed | Vaping, E-Cig Use | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05431387) |
| January 25, 2022 | NCT05206370 | A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers | Achieve Life Sciences | Phase 3 | Completed | Smoking Cessation | 792 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05206370) |
| October 6, 2020 | NCT04576949 | A Study of Cytisinicline for Smoking Cessation in Adult Smokers | Achieve Life Sciences | Phase 3 | Completed | Smoking Cessation | 810 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04576949) |
| February 20, 2019 | NCT03848208 | A Single Dose-escalation Study of Cytisine in Adult Smokers | Achieve Life Sciences | Phase 1 | Completed | Smoking Cessation | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03848208) |
| October 17, 2018 | NCT03709823 | Trial of Cytisine in Adult Smokers | Achieve Life Sciences | Phase 2 | Completed | Smoking Cessation | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03709823) |
| April 27, 2018 | NCT03509948 | A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation | Achieve Life Sciences | Phase 1 | Completed | Smoking Cessation | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03509948) |
| October 6, 2017 | NCT03303911 | A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers | Achieve Life Sciences | Phase 1/2 | Terminated | Smoking Cessation | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03303911) |
| August 31, 2017 | NCT03268343 | A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine | Achieve Life Sciences | Phase 1 | Completed | Smoking Cessation | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03268343) |
| June 11, 2013 | NCT01874561 | Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization | Achieve Life Sciences | Phase 1 | Completed | Cardiac Conduction and Repolarization | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01874561) |
| June 28, 2012 | NCT01630733 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer | Achieve Life Sciences | Phase 3 | Completed | Non-Small Cell Lung Cancer | 664 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01630733) |
| April 17, 2012 | NCT01578655 | Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer | Achieve Life Sciences | Phase 3 | Completed | Prostate Cancer | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01578655) |
| December 22, 2011 | NCT01497470 | A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug... | Achieve Life Sciences | Phase 1 | Completed | Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01497470) |
| October 18, 2011 | NCT01454089 | A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer | Achieve Life Sciences | Phase 2 | Completed | Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms | 183 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01454089) |
| August 25, 2010 | NCT01188187 | Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer | Achieve Life Sciences | Phase 3 | Completed | Prostate Cancer | 1,022 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01188187) |
| March 10, 2010 | NCT01083615 | A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men... | Achieve Life Sciences | Phase 3 | Terminated | Castrate-Resistant Prostate Cancer, Hormone Refractory Prostate Cancer | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01083615) |
| June 19, 2007 | NCT00487786 | Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer | Achieve Life Sciences | Phase 1 | Completed | Neoplasms | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00487786) |
| October 6, 2006 | NCT00385177 | Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors | Achieve Life Sciences | Phase 1 | Completed | Breast Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Pelvic Neoplasms, Lung Neoplasms | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00385177) |
| May 18, 2006 | NCT00327340 | Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC | Achieve Life Sciences | Phase 2 | Completed | Prostate Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00327340) |
| November 9, 2005 | NCT00251095 | Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer | Achieve Life Sciences | Phase 3 | Terminated | Breast Neoplasm | 821 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00251095) |
| August 30, 2005 | NCT00138658 | A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | Achieve Life Sciences | Phase 1/2 | Completed | Non-small Cell Lung Cancer | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00138658) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 2 |
| Phase 2 | 10 |
| Phase 3 | 9 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 27 |
| Terminated | 3 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Smoking Cessation | 10 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Neoplasms | 3 |
| Breast Neoplasms | 3 |
| Prostatic Neoplasms | 3 |
| Neoplasm Metastasis | 2 |
| Lung Neoplasms | 2 |
| Urologic Neoplasms | 2 |
| Urinary Bladder Neoplasms | 2 |
| Carcinoma, Transitional Cell | 2 |
| Ovarian Neoplasms | 1 |
| Vaping | 1 |
| Colorectal Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Pelvic Neoplasms | 1 |
| Renal Insufficiency | 1 |
| Ureteral Neoplasms | 1 |
| Urethral Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
- [Cleaning products suppliers in the United States](https://specstream.ai/data/businesses/cleaning-products-suppliers/united-states)
- [Health insurance offices in the United States](https://specstream.ai/data/businesses/health-insurance-offices/united-states)
- [Paving contractors in the United States](https://specstream.ai/data/businesses/paving-contractors/united-states)
- [Trailer repair shops in the United States](https://specstream.ai/data/businesses/trailer-repair-shops/united-states)
- [Buffet restaurants in the United States](https://specstream.ai/data/businesses/buffet-restaurants/united-states)
